FRC
FRC Logo
Sign InGet Access

Connect With Us

Stay updated with our latest research and insights

Fundamental Research Corp Logo

Highly ranked equity research firm providing institutional grade tools and analysis to all investors worldwide. Trusted by global investors for over 20+ years.

20+ Years
Rate us on TrustpilotLeave a review

Policies

  • Privacy Policy
  • Terms of Service
  • Disclaimer

Company

  • About Us
  • Our Team
  • Contact Us
  • Leave a Review

Resources

  • Videos
  • Research Reports
  • FAQ
  • How to use FRC

Browse

  • Stock Directory
  • Stock Screener
  • Market Intel Weekly
  • Report Archive

Trackers

  • Congress Trading
  • Senate Trading
  • Congress Net Worth
  • Commodities

© 2026 Fundamental Research Corp. All Rights Reserved.

Professional investment research since 2003

Home
Research
Get Access
Sign In
Radnostix, Inc. Stock AnalysisComprehensive stock analysis for Radnostix, Inc. (INIS) including live price, Snowflake performance metrics, financial statements, and investment research.Stock AnalysisINIS
INIS
Radnostix, Inc.
  • Company Overview
  • FRC Research
  • Financial Data
  • Peer Comparison
  • Ownership & News
INIS
Home🔹Stocks🔹Radnostix, Inc.

Radnostix, Inc.

🇺🇸INIS•OTC

Radnostix, Inc.

🇺🇸INIS•OTC
Market cap
$42.26M
Sentiment

Your view on INIS

Mkt Cap
$42.26M
Sentiment
Your view
INIS
Radnostix, Inc.
  • Company Overview
  • FRC Research
  • Financial Data
  • Peer Comparison
  • Ownership & News
INIS
Company Overview

Overview

What the company does, where it operates, and who runs it.

About Radnostix, Inc.

Industry
Drug Manufacturers - Specialty & Generic
Sector
Healthcare
CEO
Shahe Bagerdjian
Headquarters
4137 Commerce Circle, Idaho Falls, ID, US
Industry
Drug Manufacturers - Specialty & Generic
Sector
Healthcare
CEO
Shahe Bagerdjian
Headquarters
4137 Commerce Circle, Idaho Falls, ID, US
Description

Radnostix, Inc. manufactures and sells nuclear medicine calibration and reference standards, cobalt-60 products, and radiopharmaceutical and radiochemical contract manufacturing services in the United States and internationally.

It operates through five segments: Nuclear Medicine Standards, Cobalt Products, Radiochemical Products, Radiological Services, and Fluorine Products.

The Nuclear Medicine Standards segment manufactures sources and standards associated with single photon emission computed and positron emission tomography imaging, patient positioning, and calibration or operational testing of dose measuring equipment for the nuclear pharmacy industry.

It offers flood sources, dose calibrators, rod sources, flexible and rigid rulers, spot and pen point markers, and various specialty design items. The Cobalt Products segment produces bulk cobalt; fabricates cobalt capsules for radiation therapy and various industrial applications; and recycles expended cobalt sources.

The Radiochemical Products segment produces and distributes various isotopically pure radiochemicals and sodium iodide I-131 generic drug product for medical, industrial, and research applications. The Radiological Services segment provides flood source disposal and gemstones processing services.

The Fluorine Products segment is involved in the production of small-scale qualification samples of high purity fluoride gas for various industrial applications, as well as development of laboratory and analytical processes required to support the planned uranium de-conversion and fluorine extraction facility.

It sells its products directly to end users and distributors. International Isotopes Inc. was incorporated in 1995 and is headquartered in Idaho Falls, Idaho.

FRC Research

Media

Infographics, videos, and posts covering the company.

Financial Data

Stock Data

Price chart, volume, and trading data.

Fair Value

What FRC thinks it is worth vs. the current price.

FRC's fair value estimate for Radnostix, Inc., and the rating behind it. INIS last traded at $0.08; the estimate is read against that market price. FRC analysts run the firm's valuation model across the companies on this platform to estimate what each one is worth, rather than republishing a consensus average. Shows the current estimate, our rating, and when it was last revised. A free account covers 7 company valuations a month; a paid subscription is unlimited.

Financial Ratios

Profitability, returns, valuation, and leverage ratios.

Valuation, profitability, liquidity and leverage ratios for Radnostix, Inc.. Starting points for Radnostix, Inc.: EPS -$1716.08, beta 1.30 — an Drug Manufacturers - Specialty & Generic name. P/E, P/B, EV/EBITDA, margins, return on equity, current ratio and debt coverage, each shown against the company's own history.

Dividend Analysis

Yield, payout ratio, and dividend coverage metrics.

Dividend history, yield and payout sustainability for Radnostix, Inc.. Radnostix, Inc. does not currently pay a regular dividend, so this section tracks capacity rather than history. Per-share payments, yield over time, payout ratio and growth streak, with coverage measured against free cash flow.

Earnings Analysis

EPS history, beat rate, and upcoming earnings reports.

Reported vs. expected earnings history for Radnostix, Inc.. Trailing twelve-month EPS for Radnostix, Inc. stands at -$1716.08. EPS surprises by quarter, revenue against estimates, and the upcoming reporting date.

Financial Statements

Income statement, balance sheet, and cash flow statements.

Income statement, balance sheet and cash flow history for Radnostix, Inc.. Radnostix, Inc. has reported as a listed company since 1997. Annual and quarterly filings with period-over-period comparison, so you can trace how revenue, margins and cash generation have moved.

Peer Comparison

Comparables

List of peer companies in the same industry.

Radnostix, Inc. valued side by side against its closest peers. Radnostix, Inc. is measured against Drug Manufacturers - Specialty & Generic peers within the Healthcare sector. Peer-relative multiples and operating metrics, so the valuation is read in the context of its own sector rather than in isolation.

Ownership & News

Institutional Ownership

Premium

Which funds and firms own the stock.

Which institutions hold Radnostix, Inc., and how their positions are changing. At a $42.3M market value, institutional positions materially move Radnostix, Inc.'s register. Top holders, position sizes, and quarter-over-quarter accumulation or distribution from regulatory filings. Included with FRC Premium.

Insider Trading

Premium

Recent buying and selling by company executives.

Buying and selling by Radnostix, Inc. executives and directors. Shares of Radnostix, Inc. have traded between $0.03 and $0.11 over the past 52 weeks — context for the timing of the transactions below. Insider transactions as disclosed to regulators, with role, size and date — the clearest read on how the people running the company are positioned. Included with FRC Premium.

Senate Trading

Premium

U.S. Senator disclosures filed under the STOCK Act.

U.S. Senate disclosures naming Radnostix, Inc.. Radnostix, Inc. is a $42.3M Healthcare company. Senators' reported transactions in this security, alongside the fundamentals — a signal most research platforms leave out entirely. Included with FRC Premium.

House Trading

Premium

U.S. Representative disclosures filed under the STOCK Act.

U.S. House of Representatives disclosures naming Radnostix, Inc.. Representatives' reported transactions in this security, shown next to the company's fundamentals. Included with FRC Premium.

News

Latest headlines and market coverage.

Latest headlines and company announcements for Radnostix, Inc.. Coverage tracks Radnostix, Inc. within Drug Manufacturers - Specialty & Generic (Healthcare). Press releases and market coverage, newest first.

Peer companies

  • DBCCF — Decibel Cannabis Company Inc.
  • DXBRF — BellRock Brands Inc.
  • ETST — Earth Science Tech, Inc.
  • FLOOF — Flower One Holdings Inc.
  • MEDXF — Medexus Pharmaceuticals Inc.
  • MILFF — 1CM Inc.
  • MRMD — MariMed Inc.
  • PLNH — Planet 13 Holdings Inc.

More Drug Manufacturers - Specialty & Generic companies

  • AMRX — Amneal Pharmaceuticals, Inc.
  • ANIP — ANI Pharmaceuticals, Inc.
  • ANTCF — Aion Therapeutic Inc.
  • AOLS — Aeolus Pharmaceuticals, Inc.
  • APNHF — Aspen Pharmacare Holdings Limited
  • APNHY — Aspen Pharmacare Holdings Limited
  • APPB — Applied Biosciences Corp.
  • APTX.TO — Apotex Health Corp.
  • AQST — Aquestive Therapeutics, Inc.
  • AQSZF — Aequus Pharmaceuticals Inc.
  • ARSUF — Fagron N.V.
  • ARYX — ARYx Therapeutics, Inc.

News

Latest Market News